Skip to main content
SpringerLink
Log in

Anti-Leukotrienes as Novel Anti-Inflammatory Treatments in Asthma

  • Chapter
Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation, and Radiation Injury, 5

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 507))

Abstract

Asthma is a chronic inflammatory disease of the airways. Among the inflammatory cells which have been implicated in the biology of asthma are eosinophils and mast cells (l-3). Although these cells have the capacity to produce a number of distinct chemical mediators, we will focus our attention exclusively on the cysteinyl leukotrienes as inflammatory mediators in asthma. We have chosen this focus, not because we believe that leukotrienes are the only mediator of importance in asthma, but rather because in the past decade a substantial body of data has accrued concerning these entities as mediators of asthma.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Laitinen, A. and L.A. Laitinen. 1991. Cellular infiltrates in asthma and in chronic obstructive pulmonary disease.Am Rev Respir Dis143:1159–1160.

    Article  CAS  PubMed  Google Scholar 

  2. Bousquet, J., P. Chanez, J.Y. Lacoste, G. Barneon, N. Ghavanian, I. Enander, P. Venge, S. Ahlstedt, J. Simony-Lafontaine, and P. Godard. 1900. Eosinophilic inflammation in asthma.N.Engl.J.Med.323:1033–1039.

    Article  CAS  PubMed  Google Scholar 

  3. Galli, S.J. 1993. New concepts about the mast cells.N.Engl.J.Med.328:257–265.

    Article  CAS  PubMed  Google Scholar 

  4. Israel, E., E.F. Juniper, J.T. Callaghan, P.N. Mathur, M.M. Morris, A.R. Dowell, G.G. Enas, F.E. Hargreave, and J.M. Drazen. 1989. Effect of a leukotriene antagonist, LY171883, on cold air-induced bronchoconstriction in asthmatics.Am Rev Respir Dis140:1348–1353.

    Article  CAS  PubMed  Google Scholar 

  5. Israel, E., R. Dermarkarian, M. Rosenberg, R. Sperling, G. Taylor, P. Rubin, and J.M. Drazen. 1990. The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dryair. N.Engl.J.Med.323:1740–1744.

    Article  CAS  Google Scholar 

  6. Manning, P.J., R.M. Watson, D.J. Margolskee, V.C. Williams, J.I. Schwartz, and P.M. O’Byrne. 1990. Inhibition of exercise-induced bronchoconstriction by MK-571, a potent leukotriene D4-receptor antagonist.N.Engl.J.Med.323:1736–1739.

    Article  CAS  PubMed  Google Scholar 

  7. Finnerty, J.P., R. Wood-Baker, H. Thompson, and S.T. Holgate. 1992. Role of leukotrienes in exercise-induced asthma: inhibitory effect of ICI 204219, a potent LTD, receptor antagonist.Am Rev Respir Dis145:746–749.

    Article  CAS  PubMed  Google Scholar 

  8. Makker, H.K., L.C. Lau, H.W. Thompson, S.M. Binks, and S.T. Holgate. 1993. The protective effect of inhaled leukotriene-D4receptor antagonist ICI-204,219 against exercise-induced asthma.Am Rev Respir Dis147:1413–1418.

    Article  CAS  PubMed  Google Scholar 

  9. Adelroth, E., M.D. Inman, E. Summers, D. Pace, M. Modi, and P.M. Obyme. 1997. Prolonged protection against exercise-induced bronchoconstriction by the leukotriene D4-receptor antagonist cinalukast.J Allerg. Clin Immunol99:210–215.

    Article  CAS  Google Scholar 

  10. Inman, M.D., and P.M. O’Byrne. 1996. The affect of regular inhaled albuterol on exercise-induced bronchoconstriction.Am.J.Respir.Crit.CareMed. 153:65–69.

    Article  Google Scholar 

  11. Reiss, T.F., P. Chervinsky, R.J. Dockhorn, S. Shingo, B. Seindenberg, T.B. Edwards, and et al. 1998. Montelukast, a once daily leukotriene receptor antagonist in the treatment of chronic asthma.Arch Int Med158:1213–1220.

    Article  CAS  Google Scholar 

  12. Reiss, T.F., C.A. Sorkness, W. Stricker, A. Botto, W.W. Busse, S. Kundu, and J. Zhang. 1997. Effects of mntelukast (MK-0476), a potent cysteinyl leukotriene receptor antagonist, on bronchodilatation in asthmatic subjects treated with and without inhaled corticosteroids.Thorax52:45–48.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  13. Dahlen, S.E., B. Dahlen, E. Elliason, H. Johansson, T. Bjorck, M. Kumlin, K. Boo, J. Whitney, S. Binks,B. King, and et al. 1991. Inhibition of allergic bronchoconstriction in asthmatics by the leokotrieneantagonist ICI-204,219.Adv.Prost.Thromb.Leukot.Res21A:461–464.

    CAS  Google Scholar 

  14. Taylor, I.K., K.M. O’Shaughnessy, R.W. Fuller, and C.T. Dollery. 1991. Effect of cysteinyl-leukotriene receptor antagonist ICI-204,219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects.Lancet337:690–694.

    Article  CAS  PubMed  Google Scholar 

  15. Findlay, S.R., J.M. Barden, C.B. Easley, and M. Glass. 1992. Effect of the oral leukotriene anatagonist, ICI-204,219 on antigen-induced bronchoconstriction in subjects with asthma.J. Allergy Clin. Immunol.89:1040–1045.

    Article  CAS  PubMed  Google Scholar 

  16. Rasmussen, J.B., D.J. Margolskee, L.O. Eriksson, V.C. Williams, and K.E. Anderson. 1991. Leukotriene (LT) D4 is involved in antigen-induced asthma: a study with the LTD4receptor antagonist, MK-571.Ann. N. Y Acad. Sci.629:436–436.

    Article  CAS  PubMed  Google Scholar 

  17. Gaddy, J.N., D.J. Margolskee, R.K. Bush, V.C. Williams, and W.W. Busse. 1992. Bronchodilation with a potent and selective leukotriene D4 (LTD4) antagonist (MK-571) in patients with asthma.Am Rev Respir Dis146:358–363.

    Article  CAS  PubMed  Google Scholar 

  18. Impens, N., T.F. Reiss, J.A. Teahan, M. Desmet, T.H. Rossing, S. Shingo, Z. Ji, W. Schandevyl, R. Verbesselt, and A.G. Dupont. 1993. Acute bronchodilation with an intravenously administered leukotriene-D(4) antagonist, MK-679.Am Rev Respir Dis147:1442–1446.

    Article  CAS  PubMed  Google Scholar 

  19. Oshaughnessy, K.M., I.K. Taylor, B. Oconnor, F. Oconnell, H. Thompson, and C.T. Dollery. 1993. Potent leukotriene-D(4) receptor antagonist ICI-204,219 given by the inhaled route inhibits the early but not the late phase of allergen-induced bronchoconstriction.Am Rev Respir Dis147:1431–1435.

    Article  CAS  Google Scholar 

  20. Friedman, B.S., E.H. Bel, A. Buntinx, W. Tanaka, Y.H.R. Han, S. Shingo, R. Spector, and P. Sterk. 1993. Oral leukotriene inhibitor (MK-886) blocks allergen-induced airway responses.Am Rev Respir Dis147:839–844.

    Article  CAS  PubMed  Google Scholar 

  21. Roquet, A., B. Dahlen, M. Kumlin, E. Ihre, G. Anstren, S. Binks, and S.E. Dahlen. 1997. Combined antagonism of leukotrienes and histamine produces predominant inhibition of allergen-induced early and late phase airway obstruction in asthmatics.Amer.J.Respir.Crit.Care Med.155:1856–1863.

    Article  CAS  Google Scholar 

  22. Cloud, M.L., G.C. Enas, J. Kemp, T. Platts-Mills, L.C. Altman, R. Townley, D. Tinkelman, T. King, Jr., E. Middleton, A.L. Sheffer, and et al. 1989. A specific LTD4/LTE4-receptor antagonist improves pulmonary function in patients with mild, chronic asthma. AmRev Respir Dis140:1336–1339.

    Article  CAS  PubMed  Google Scholar 

  23. Israel, E., P. Rubin, J.P. Kemp, J. Grossman, W.E. Pierson, S.C. Siegel, D. Tinkelman, J.J. Murray, W. Busse, A.T. Segal, J. Fish, H.B. Kaiser, D. Ledford, S. Wenzel, R. Rosenthal, J. Cohn, C. Lanni, H. Pearlman, P. Karahalios, and J.M. Drazen. 1993. The effect of inhibition of 5-lipoxygenase by zileuton in mild to moderate asthma.Ann.Intern.Med.119:1059–1066.

    Article  CAS  PubMed  Google Scholar 

  24. Spector, S.L., L.J. Smith, M. Glass, B.K. Birmigham, E.A. Bronsky, K.D. Dunn, J.E. Fish, J. Grossman, W. Howland, M.C. Minkwitz, J.S. Larsen, R.A. Nathan, S.I. Rennard, E.S. Schulman, A. segal, and L.M. Seltzer. 1994. Effects of 6 weeks of therapy with oral doses of ICI-204,219 a leukotriene D4 receptor antagonist, in subjects with bronchial asthma.Am.J.Respir.Crit.Care Med150:618–623.

    Article  CAS  PubMed  Google Scholar 

  25. Barnes, N.C., and J.C. Pujet. 1997. Pranlukast, a novel leukotriene receptor antagonist: results of the first european, placebo controlled, multicenter clinical study in asthma.Thorax52:523–527.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  26. Drazen, J.M., E. Israel, and P.M. Obyrne. 1999. Treatment of asthma with drugs modifying the leukotriene pathway.N.Engl.J.Med.340:197–206.

    Article  CAS  PubMed  Google Scholar 

  27. Reiss, T.F., P. Chervinsky, R.J. Dockhorn, S. Shingo, B. Seindenberg, and T.B. Edwards. 1998. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group.Arch.lntern. Med.158:1213–1220.

    Article  CAS  Google Scholar 

  28. Fish, J.E., J.P. Kemp, R.F. Lockey, M. Glass, L.A. Hanby, and C.M. Bonuccelli. 1997. Zafirlukast for symptomatic mild to moderate asthma: a 13-week multicenter study. The Zafirlukast Trialists Group.Clin.Ther.19:675–690.

    Article  CAS  PubMed  Google Scholar 

  29. Israel, E., J. Cohn, L. Dube, and J.M. Drazen. 1996. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma: a randomized controlled trial.JAMA275:931–936.

    Article  CAS  PubMed  Google Scholar 

  30. Liu, M.C., L.M. Dube, and J. Lancaster. 1996. Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trial. Zileuton Study Group.J Allergy Clin. Immunol98:859–871.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Combined Program in Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, 75 Francis Street, Boston, MA, 02115

    Jeffrey M. Drazen M.D.

Authors
  1. Jeffrey M. Drazen M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Wayne State University, Detroit, Michigan, USA

    Kenneth V. Honn

  2. Vanderbilt University School of Medicine, Nashville, Tennessee, USA

    Lawrence J. Marnett

  3. Free University Berlin, Berlin, Germany

    Santosh Nigam

  4. University of California-San Diego, La Jolla, California, USA

    Edward Dennis

  5. Brigham and Women’s Hospital, Boston, Massachusetts, USA

    Charles Serhan

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Springer Science+Business Media New York

About this chapter

Cite this chapter

Drazen, J.M. (2002). Anti-Leukotrienes as Novel Anti-Inflammatory Treatments in Asthma. In: Honn, K.V., Marnett, L.J., Nigam, S., Dennis, E., Serhan, C. (eds) Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation, and Radiation Injury, 5. Advances in Experimental Medicine and Biology, vol 507. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-0193-0_33

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-0193-0_33

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-4960-0

  • Online ISBN: 978-1-4615-0193-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation